Routine diagnostics and studies of Alzheimer’s disease might benefit form the noninvasive optical imaging of amyloid-$beta$ plaques in the brain. A rational design strategy for in vivo amyloid-imaging agents that enter the brain and selectively stain amyloid plaques is presented (see picture), and properties of a promising lead biomarker candidate are reported. [on SciFinder(R)]